Search hospitals > Illinois > Rockford

OSF Saint Anthony Medical Center

Claim this profile
Rockford, Illinois 61108
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Colorectal Cancer
65 reported clinical trials
2 medical researchers
Photo of OSF Saint Anthony Medical Center in RockfordPhoto of OSF Saint Anthony Medical Center in RockfordPhoto of OSF Saint Anthony Medical Center in Rockford

Summary

OSF Saint Anthony Medical Center is a medical facility located in Rockford, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. OSF Saint Anthony Medical Center is involved with conducting 65 clinical trials across 112 conditions. There are 2 research doctors associated with this hospital, such as Shylendra B. Sreenivasappa and Iftekhar U. Ahmad.

Area of expertise

1Cancer
Global Leader
OSF Saint Anthony Medical Center has run 17 trials for Cancer. Some of their research focus areas include:
Stage II
HER2 positive
Stage I
2Breast Cancer
Global Leader
OSF Saint Anthony Medical Center has run 16 trials for Breast Cancer. Some of their research focus areas include:
ER positive
Stage II
HER2 positive

Top PIs

Clinical Trials running at OSF Saint Anthony Medical Center

Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Squamous Cell Carcinoma
ALK Gene Rearrangement
Colorectal Cancer
Adenoma
Image of trial facility.

Support Program

for Breast Cancer

This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at OSF Saint Anthony Medical Center?
OSF Saint Anthony Medical Center is a medical facility located in Rockford, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. OSF Saint Anthony Medical Center is involved with conducting 65 clinical trials across 112 conditions. There are 2 research doctors associated with this hospital, such as Shylendra B. Sreenivasappa and Iftekhar U. Ahmad.